1. Home
  2. AKBA vs CTBI Comparison

AKBA vs CTBI Comparison

Compare AKBA & CTBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • CTBI
  • Stock Information
  • Founded
  • AKBA 2007
  • CTBI 1903
  • Country
  • AKBA United States
  • CTBI United States
  • Employees
  • AKBA N/A
  • CTBI N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • CTBI Major Banks
  • Sector
  • AKBA Health Care
  • CTBI Finance
  • Exchange
  • AKBA Nasdaq
  • CTBI Nasdaq
  • Market Cap
  • AKBA 861.7M
  • CTBI 1.0B
  • IPO Year
  • AKBA 2014
  • CTBI N/A
  • Fundamental
  • Price
  • AKBA $2.95
  • CTBI $56.63
  • Analyst Decision
  • AKBA Strong Buy
  • CTBI Buy
  • Analyst Count
  • AKBA 5
  • CTBI 3
  • Target Price
  • AKBA $6.90
  • CTBI $59.00
  • AVG Volume (30 Days)
  • AKBA 3.9M
  • CTBI 43.9K
  • Earning Date
  • AKBA 11-06-2025
  • CTBI 10-15-2025
  • Dividend Yield
  • AKBA N/A
  • CTBI 3.71%
  • EPS Growth
  • AKBA N/A
  • CTBI 17.47
  • EPS
  • AKBA N/A
  • CTBI 5.08
  • Revenue
  • AKBA $203,733,000.00
  • CTBI $253,839,000.00
  • Revenue This Year
  • AKBA $38.23
  • CTBI $20.43
  • Revenue Next Year
  • AKBA $38.17
  • CTBI $4.40
  • P/E Ratio
  • AKBA N/A
  • CTBI $11.26
  • Revenue Growth
  • AKBA 16.75
  • CTBI 12.25
  • 52 Week Low
  • AKBA $1.24
  • CTBI $44.60
  • 52 Week High
  • AKBA $4.08
  • CTBI $61.67
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 40.51
  • CTBI 47.09
  • Support Level
  • AKBA $2.92
  • CTBI $57.55
  • Resistance Level
  • AKBA $3.15
  • CTBI $59.67
  • Average True Range (ATR)
  • AKBA 0.14
  • CTBI 0.93
  • MACD
  • AKBA 0.01
  • CTBI -0.27
  • Stochastic Oscillator
  • AKBA 18.75
  • CTBI 1.14

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About CTBI Community Trust Bancorp Inc.

Community Trust Bancorp Inc is a bank holding company. The Bank owns all the capital stock of one commercial bank and one trust company, serving small and mid-sized communities in eastern, north-eastern, central, and southcentral Kentucky, southern West Virginia, and north-eastern Tennessee. Through its subsidiaries, the Bank is engaged in commercial and personal banking and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals, and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes; and providing funds transfer services.

Share on Social Networks: